In March, a large number of senior executives of pharmaceutical companies left, including more than 8 deputy general managers

Looking back at the pharmaceutical industry in March, the tide of departures continued
.
According to incomplete statistics in the industry, a total of 28 senior executives of pharmaceutical companies resigned in March, including Hualan Biotechnology and Shanghai Pharmaceuticals
.
The reasons for resignation are mainly personal reasons
.
Judging from the positions left by these executives, the general manager, deputy general manager and vice president are still the focus of the industry
.
With only the position of deputy general manager, more than 8 deputy general managers have resigned in March, involving 6 enterprises
.
Among them, Weili Medical issued an announcement on the evening of March 31 saying that due to work adjustment, Mr.
Huang An applied for his resignation as the company's deputy general manager
.
After his resignation, he will hold a management position in Guangzhou Weili Jianyi Medical Equipment Co.
, Ltd.
, a subsidiary of the company
.
As of the disclosure date of this announcement, Mr.
Huang An does not hold any shares of the company
.
On March 30, Hualan Bio announced that the company's executives had undergone personnel changes, saying that three deputy general managers had resigned
.
Among them, Pan Ruowen resigned as deputy general manager due to job change, Wang Qiping resigned due to retirement, and An Wenqi resigned due to job change
.
The company's main business is the research and development, production and sales of blood products, vaccines, and genetically engineered products
.
On March 11, Changshan Pharmaceutical announced that Mr.
Huang Guosheng had resigned from the position of deputy general manager of the company due to personal reasons
.
will no longer hold any position in the company
.
Up to now, Mr.
Huang Guosheng holds about 740,000 shares of the company
.
On March 7, Doray Pharmaceuticals issued an announcement that the company's board of directors recently received a written resignation report submitted by the company's deputy general manager, Mr.
Yao Hongjun.
Mr.
Yao Hongjun applied for his resignation as deputy general manager due to personal reasons.
Do not hold other positions in the company
.
It is worth mentioning that Dorui Medicine carried out an "exchange" that month.
The company announced on the evening of March 24 that, according to the nomination of the company's general manager, the company's board of directors agreed to appoint Mr.
Ao Bo as the company's deputy general manager
.
On March 3, Lepu Medical announced that the company received the resignation application submitted by the company's deputy general manager Lin Yi on March 3, 2022
.
Lin Yi applied to resign from the position of deputy general manager of the company due to personal reasons, and will no longer hold any position in the company after resignation
.
In addition to the resignation of the deputy general manager, the company's top management changed frequently during the month
.
On March 24, the company underwent an industrial and commercial change.
Among the senior executives, Pu Zhongjie stepped down as executive director and general manager, and Zhang Zhibin took over
.
Equity penetration data shows that the company is a wholly-owned subsidiary of Lepu Medical
.
On March 1, Guanhao Biological announced that the company recently received a written resignation report from the company's deputy general manager Cheng Shunqiao, who applied for resignation from the position of the company's deputy general manager due to personal reasons, and will no longer serve as the company after his resignation.
any position
.
As of the disclosure date of this announcement, Cheng Shunqiao did not hold any shares in the company
.
In addition to the departure of senior executives, there are also a number of new deputy general managers of pharmaceutical companies
.
For example, the above-mentioned Dorui Medicine, for example, on the evening of March 24, Haier Bio announced that the company held a board meeting on March 24 to consider and approve the "Proposal on the Appointment of the Company's Deputy General Manager", agreeing to the company's appointment of a general manager to nominate Zhang Ji will serve as the deputy general manager of the company, and his term of office will start from the date of deliberation and approval by the board of directors and end on the date of the second session of the board of directors
.
According to the data, before joining Haier Bio, Ms.
Zhang Ji served as the Vice President of Neusoft Medical and Senior Director of Human Resources and Administration Center; since July 2021, she has been the General Manager of Global Human Resources of Haier Bio
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.